Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ECT 204

Next Previous
Search
Drug Profile

ECT 204

Alternative Names: ECT-204; ECT204 ARTEMIS® T cell therapy - Eureka Therapeutics; ECT204 T cells - Eureka Therapeutics; ECT204 T-cell therapy - Eureka Therapeutics; GPC3 targeting ARTEMIS® T-cell therapy - Eureka Therapeutics; GPC3 targeting T-cell therapy - Eureka Therapeutics; JWATM-204; JWCAR-204

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eureka Therapeutics
  • Developer Eureka Therapeutics; JW Therapeutics
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Liver cancer
  • Preclinical Adenocarcinoma; Non-small cell lung cancer

Most Recent Events

  • 28 Apr 2025 No recent reports of development identified for phase-I development in Liver-cancer(Late-stage disease, Second-line therapy or greater) in China (IV, Injection)
  • 06 Sep 2022 Preclinical trials in Adenocarcinoma in China (Parenteral) prior to September 2022 (JW Therapeutics website, September 2022)
  • 06 Sep 2022 Preclinical trials in Non-small cell lung cancer in China (Parenteral) prior to September 2022 (JW Therapeutics website, September 2022)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top